Abstract
Drugs that inhibit HIV replication have been shown to have clinical utility in patients with HIV infection. However, the immunological improvement induced by available anti-HIV therapies in patients with AIDS is incomplete and transient. Explanations for this may include immunological barriers to complete reconstitution, low therapeutic indices of the available drugs, and the development of viral resistance. An understanding of these processes may provide important leads for the development of improved therapy for AIDS.
MeSH terms
-
Acquired Immunodeficiency Syndrome / immunology
-
Acquired Immunodeficiency Syndrome / therapy*
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Dideoxynucleosides / pharmacology
-
Dideoxynucleosides / therapeutic use
-
Drug Resistance, Microbial
-
Drug Therapy, Combination
-
HIV / drug effects*
-
HIV Infections / immunology
-
HIV Infections / therapy*
-
HIV Protease Inhibitors / pharmacology
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Immunotherapy
-
Virus Replication / drug effects
Substances
-
Antiviral Agents
-
Dideoxynucleosides
-
HIV Protease Inhibitors